Granted Patent
B2
US 12,441,969 · App. 17/689,745 · Granted Oct 14, 2025
Delivery of materials to anucleate cells
Inventors:
Armon R. Sharei (Cambridge, MA); Klavs F. Jensen (Lexington, MA); James Robbins Abshire (Cambridge, MA); Jacquin Clarence Niles (Arlington, MA)
Assignee:
Massachusetts Institute of Technology
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The current subject matter includes methods, systems, articles, and techniques to deliver material to anucleate cells, such as red blood cells. Using a rapid deformation based microfluidic system, loading of red blood cells with macromolecules of different sizes has been shown. Although delivery to some mammalian cells, such as cancer cell lines and fibroblasts had been previously demonstrated using this technique, those designs were incompatible with RBCs that have dramatically different physical properties. Through the use of smaller constriction sizes, high speeds and different buffers successful delivery to red blood cells can be achieved. By enabling robust delivery to red blood cells in a simple, scalable manner, the current subject matter can be implemented in a diversity of applications that deliver material to study red blood cell diseases and/or use red blood cells as a therapeutic platform. Related apparatus, systems, techniques, and articles are also described.
Claims (20)
1. A composition comprising a mammalian anucleate cell comprising an intracellular payload, wherein the composition is prepared by a method comprising passing a suspension comprising the anucleate cell through a microfluidic channel that includes a cell-deforming constriction causing perturbations of a membrane of the anucleate cell large enough for the payload to pass through, wherein the constriction comprises a width, a length, and a depth, wherein the width of the constriction is less than 4 micrometers; and incubating the anucleate cell in a solution comprising the payload for a predetermined time before or after the anucleate cell passes through the constriction, wherein the anucleate cell is one or more of red blood cells and reticulocytes.
2. The composition of claim 1 , wherein the anucleate cell in suspension comprises unmodified blood.
3. The composition of claim 1 , wherein the width is less than the largest diameter of the anucleate cell.
4. The composition of claim 1 , wherein the width is about 20% to about 99% of the largest diameter of the anucleate cell.
5. The composition of claim 1 , wherein the method to prepare the composition further comprises applying a pressure to the suspension for passing the suspension through the cell-deforming constriction.
6. The composition of claim 1 , wherein the solution comprising the payload comprises one or more of proteins, peptides, small molecules, nucleic acids, lipids, carbohydrates, macromolecules, vitamins, polymers, fluorescent dyes, fluorophores, carbon nanotubes, quantum dots, nanoparticles, dextran polymers, and steroids.
7. The composition of claim 1 , wherein a cross-section of the microfluidic channel is selected from the group consisting of circular, elliptical, an elongated slit, square, hexagonal, and triangular.
8. The composition of claim 1 , wherein the length of the constriction is 30 micrometers or less.
9. The composition of claim 8 , wherein the length of the constriction is between 10 micrometers and 30 micrometers.
10. The composition of claim 1 , wherein the depth of the constriction is between 1 μm and 1 mm.
11. The composition of claim 10 , wherein the depth of the constriction is between 1 μm and 20 μm.
12. The composition of claim 1 , wherein incubating the anucleate cell in the solution comprising the payload comprises incubating the cell for 0.0001 seconds to 20 minutes.
13. The composition of claim 1 , wherein the anucleate cell is a red blood cell.
14. The composition of claim 13 , wherein the width of the constriction is greater than 0.5 micrometers and less than 4 micrometers.
15. The composition of claim 1 , wherein the width of the constriction is greater than 0.5 micrometers and less than 4 micrometers.
16. The composition of claim 13 , wherein the width is about 20% to about 99% of the largest diameter of the anucleate cell.
17. The composition of claim 16 , wherein the solution comprising the payload comprises one or more of proteins, peptides, small molecules, nucleic acids, lipids, carbohydrates, macromolecules, vitamins, polymers, fluorescent dyes, fluorophores, carbon nanotubes, quantum dots, nanoparticles, dextran polymers, and steroids.
18. The composition of claim 1 , wherein the composition is a therapeutic composition for a disease or disorder.
19. The composition of claim 13 , wherein the composition is a therapeutic composition for a disease or disorder.
20. The composition of claim 1 , wherein the intracellular payload comprises one or more of chloroquine, atovaquone-proguanil, artemether/lumefantrine, quinine sulfate, mefloquine, hydroxychloroquine, quinidine, sulfadoxine/pyrimethamine, amodiaquine, sulfonamides, halofantrine, doxycycline, tetracycline, hydrea, acyclovir, ganciclovir, valacyclovir, penciclovir, tripeptides, or tetra-peptides.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 19, 2023
From: SHAREI, ARMON; JENSEN, KLAVS; ABSHIRE, JAMES ROBBINS; NILES, JACQUIN CLARENCE
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 063700/0324 →
Continuity (4)
Continuation
PCTUS2016041653
· Jul 8, 2016
Provisional Application
62190677
· Jul 9, 2015
References Cited (380)
US 4055799A
· Coster et al.
· 1977
[cited by applicant]
US 4376634A
· Prior et al.
· 1983
[cited by applicant]
US 4835457A
· Hanss et al.
· 1989
[cited by applicant]
US 5023054A
· Sato et al.
· 1991
[cited by applicant]
US 5427663A
· Austin et al.
· 1995
[cited by applicant]
US 5643577A
· Pang et al.
· 1997
[cited by applicant]
US 5658892A
· Flotte et al.
· 1997
[cited by applicant]
US 5842787A
· Kopf-Sill et al.
· 1998
[cited by applicant]
US 5951976A
· Segal
· 1999
[cited by applicant]
US 6133503A
· Scheffler
· 2000
[cited by applicant]
US 6156181A
· Parce et al.
· 2000
[cited by applicant]
US 6186660B1
· Kopf-Sill et al.
· 2001
[cited by applicant]
US 6218166B1
· Ravindranath et al.
· 2001
[cited by applicant]
US 6410329B1
· Hansen et al.
· 2002
[cited by applicant]
US 6461867B1
· Cai et al.
· 2002
[cited by applicant]
US 6562616B1
· Toner et al.
· 2003
[cited by applicant]
US 7109034B2
· Orwar et al.
· 2006
[cited by applicant]
US 7148059B1
· Tillotson et al.
· 2006
[cited by applicant]
US 7413733B2
· Traversari et al.
· 2008
[cited by applicant]
US 7704743B2
· Fedorov et al.
· 2010
[cited by applicant]
US 7993821B2
· Chiu
· 2011
[cited by applicant]
US 8211656B2
· Hyde et al.
· 2012
[cited by applicant]
US 8669044B2
· Chiu
· 2014
[cited by applicant]
US 8679751B2
· Huang
· 2014
[cited by applicant]
US 8697359B1
· Zhang
· 2014
[cited by applicant]
US 8844570B2
· Glick
· 2014
[cited by applicant]
US 8993348B2
· Wheeler et al.
· 2015
[cited by applicant]
US 9005579B2
· Nowinski et al.
· 2015
[cited by applicant]
US 9017991B2
· Diefenbach
· 2015
[cited by applicant]
US 9157550B2
· Wheeler et al.
· 2015
[cited by applicant]
US 9255245B2
· Bernick et al.
· 2016
[cited by applicant]
US 9364504B2
· Godfrin et al.
· 2016
[cited by applicant]
US 9458489B2
· Lim et al.
· 2016
[cited by applicant]
US 9526823B2
· Yoshioka
· 2016
[cited by applicant]
US 9950049B2
· Godfrin et al.
· 2018
[cited by applicant]
US 20030133922A1
· Kasha, Jr.
· 2003
[cited by applicant]
US 20040176282A1
· Dalby et al.
· 2004
[cited by applicant]
US 20050026283A1
· Ormar et al.
· 2005
[cited by applicant]
US 20060134067A1
· Liu et al.
· 2006
[cited by applicant]
US 20060134772A1
· Miles et al.
· 2006
[cited by applicant]
US 20070249038A1
· Adamo et al.
· 2007
[cited by applicant]
US 20080241844A1
· Kellogg
· 2008
[cited by applicant]
US 20080311140A1
· Lee et al.
· 2008
[cited by applicant]
US 20090209039A1
· Adamo et al.
· 2009
[cited by applicant]
US 20090280518A1
· Adamo et al.
· 2009
[cited by applicant]
US 20100203068A1
· Betz et al.
· 2010
[cited by applicant]
US 20100249621A1
· Ichitani et al.
· 2010
[cited by applicant]
US 20110014616A1
· Holmes et al.
· 2011
[cited by applicant]
US 20110053241A1
· Den Tooner et al.
· 2011
[cited by applicant]
US 20110091973A1
· Glaser
· 2011
[cited by applicant]
US 20110289043A1
· Suresh et al.
· 2011
[cited by applicant]
US 20110300205A1
· Geall et al.
· 2011
[cited by applicant]
US 20120064505A1
· Suresh et al.
· 2012
[cited by applicant]
US 20120107925A1
· Li et al.
· 2012
[cited by applicant]
US 20120207745A1
· Godfrin et al.
· 2012
[cited by applicant]
US 20120222143A1
· Fahrenkrug et al.
· 2012
[cited by applicant]
US 20130023051A1
· Bundock et al.
· 2013
[cited by applicant]
US 20130065314A1
· MacMillan
· 2013
[cited by applicant]
US 20150196913A1
· Liu
· 2015
[cited by applicant]
US 20170326213A1
· Jajosky et al.
· 2017
[cited by applicant]
US 20190017072A1
· Ditommaso et al.
· 2019
[cited by applicant]
US 20190093073A1
· Sharei et al.
· 2019
[cited by applicant]
US 20190382796A1
· Gilbert et al.
· 2019
[cited by applicant]
US 20200277566A1
· Sharei et al.
· 2020
[cited by applicant]
US 20210138050A1
· Loughhead et al.
· 2021
[cited by applicant]
US 20220105166A1
· Sharei et al.
· 2022
[cited by applicant]
US 20230097861A1
· Ditommaso et al.
· 2023
[cited by applicant]
US 20230130686A1
· Sharei et al.
· 2023
[cited by applicant]
US 20230357782A1
· Sharei et al.
· 2023
[cited by applicant]
CN 101031339A
· 2007
[cited by applicant]
CN 101031641A
· 2007
[cited by applicant]
CN 102250842A
· 2011
[cited by applicant]
CN 106244543A
· 2016
[cited by applicant]
EP 0882448A1
· 1998
[cited by applicant]
EP 1225228A2
· 2002
[cited by applicant]
EP 2169070A1
· 2010
[cited by applicant]
EP 168220788
· 2019
[cited by applicant]
JP H01196566A
· 1989
[cited by applicant]
JP H03257366A
· 1991
[cited by applicant]
JP 2010025852A
· 2010
[cited by applicant]
JP 2011163830A
· 2011
[cited by applicant]
JP 2013536848A
· 2013
[cited by applicant]
JP 6235085B2
· 2017
[cited by applicant]
KR 100760309B1
· 2007
[cited by applicant]
KR 100891487B1
· 2009
[cited by applicant]
KR 20110009422A
· 2011
[cited by applicant]
KR 20140115560A
· 2014
[cited by applicant]
KR 20140134524A
· 2014
[cited by applicant]
WO WO8500748A1
· 1985
[cited by applicant]
WO WO9720570A1
· 1997
[cited by applicant]
WO WO0007630A1
· 2000
[cited by applicant]
WO WO0267863A2
· 2002
[cited by applicant]
WO WO0320039A1
· 2003
[cited by applicant]
WO WO2004001424A1
· 2003
[cited by applicant]
WO WO2006010521A1
· 2006
[cited by applicant]
WO WO2006095330A2
· 2006
[cited by applicant]
WO WO2006105251A2
· 2006
[cited by applicant]
WO WO2007067032A1
· 2007
[cited by applicant]
WO WO2007097934A2
· 2007
[cited by applicant]
WO WO2008021465A2
· 2008
[cited by applicant]
WO WO2008133755A2
· 2008
[cited by applicant]
WO WO2009056332A1
· 2009
[cited by applicant]
WO WO2010016800A1
· 2010
[cited by applicant]
WO WO2010077290A1
· 2010
[cited by applicant]
WO WO2010105135A1
· 2010
[cited by applicant]
WO WO2010129671A2
· 2010
[cited by applicant]
WO WO2010145849A2
· 2010
[cited by applicant]
WO WO2011051346A1
· 2011
[cited by applicant]
WO WO2011119492A2
· 2011
[cited by applicant]
WO WO2012069568A2
· 2012
[cited by applicant]
WO WO2012097450A1
· 2012
[cited by applicant]
WO WO2012106536A2
· 2012
[cited by applicant]
WO WO2012118799A2
· 2012
[cited by applicant]
WO WO2012162779A1
· 2012
[cited by applicant]
WO WO2013059343A1
· 2013
[cited by applicant]
WO WO2013185032A1
· 2013
[cited by applicant]
WO WO2014065596A1
· 2014
[cited by applicant]
WO WO2014106629A1
· 2014
[cited by applicant]
WO WO2014106631A1
· 2014
[cited by applicant]
WO WO2014120956A1
· 2014
[cited by applicant]
WO WO2014165707A2
· 2014
[cited by applicant]
WO WO2015023982A1
· 2015
[cited by applicant]
WO WO2015061458A1
· 2015
[cited by applicant]
WO WO2015153102A1
· 2015
[cited by applicant]
WO WO2015161276A2
· 2015
[cited by applicant]
WO WO2016003485A1
· 2016
[cited by applicant]
WO WO2016070136A1
· 2016
[cited by applicant]
WO WO2016077761A1
· 2016
[cited by applicant]
WO WO2016109864A1
· 2016
[cited by applicant]
WO WO2016115179A1
· 2016
[cited by applicant]
WO WO2016183482A1
· 2016
[cited by applicant]
WO WO2017005700A1
· 2017
[cited by applicant]
WO WO2017008063A1
· 2017
[cited by applicant]
WO WO2017041050A1
· 2017
[cited by applicant]
WO WO2017041051A1
· 2017
[cited by applicant]
WO WO2017106899A2
· 2017
[cited by applicant]
WO WO2017123644A1
· 2017
[cited by applicant]
WO WO2017123646A1
· 2017
[cited by applicant]
WO WO2017123663A1
· 2017
[cited by applicant]
WO WO2017192785A1
· 2017
[cited by applicant]
WO WO2017192786A1
· 2017
[cited by applicant]
WO WO2018089497A1
· 2018
[cited by applicant]
Muzykantov “Drug delivery by red blood cells: vascular carriers designed by mother nature.” Expert Opinion on Drug Delivery 7.4 (2010): 403-427. (Year: 2010).
[cited by examiner]
Ahn et al. “Treatment of autoimmune hemolytic anemia with vinca-loaded platelets.” JAMA 249.16 (1983): 2189-2194. (Year: 1983).
[cited by examiner]
Freitas Jr. Nanomedicine, vol. I: Basic Capabilities. 1999:1 page.
[cited by applicant]
Hori et al., Control of regulatory T cell development by the transcription factor Foxp3. Science. Feb. 14, 2003;299(5609):1057-61. doi: 10.1126/science.1079490. Epub Jan. 9, 2003.
[cited by applicant]
Loschko et al., Antigen targeting to plasmacytoid dendritic cells via Siglec-H inhibits Th cell-dependent autoimmunity. J Immunol. Dec. 15, 2011;187(12):6346-56. doi: 10.4049/jimmunol.1102307. Epub Nov. 11, 2011.
[cited by applicant]
Ring et al., Targeting of autoantigens to DEC205
[cited by applicant]
Tsai et al., Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity. Apr. 23, 2010;32(4):568-80. doi: 10.1016/j.immuni.2010.03.015. Epub Apr. 8, 2010.
[cited by applicant]
Extended European Search Report for EP App. No. 16822078.8 mailed Jan. 30, 2019.
[cited by applicant]
International Preliminary Report on Patentability (Chapter I) for PCT/US2016/041653 mailed Jan. 18, 2018.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2016/041653 mailed Oct. 4, 2016.
[cited by applicant]
Extended European Search Report for EP App. No. 16737769.6 mailed May 3, 2018.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2016/013113 dated Mar. 21, 2016.
[cited by applicant]
International Preliminary Report on Patentability (Chapter I) for PCT/US2016/013113 mailed Jul. 27, 2017.
[cited by applicant]
Partial Supplementary European Search Report for EP App. No. 15859824.3 mailed Jun. 11, 2018.
[cited by applicant]
Extended European Search Report mailed Sep. 11, 2018 for Application No. EP 15859824.3.
[cited by applicant]
International Preliminary Report on Patentability (Chapter I) for PCT/US2015/060689 mailed May 16, 2017.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2015/060689 mailed Feb. 1, 2016.
[cited by applicant]
Partial Supplementary European Search Report for EP App. No. 15855640.7 mailed May 30, 2018.
[cited by applicant]
Extended European Search Report mailed Sep. 5, 2018 for Application No. EP 15855640.7.
[cited by applicant]
International Preliminary Report on Patentability (Chapter I) for PCT/US2015/058489 mailed May 2, 2017.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2015/058489 mailed Mar. 11, 2016.
[cited by applicant]
European Search Report for EP App. No. 14836593.5 mailed Feb. 23, 2017.
[cited by applicant]
Extended European Search Report for EP Application No. 21158382.8 dated Jun. 11, 2021.
[cited by applicant]
International Preliminary Report on Patentability (Chapter I) for PCT/US2014/051343 mailed Feb. 16, 2016.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2014/051343 mailed Dec. 18, 2014.
[cited by applicant]
European Search Report for EP App. No. 12841329.1 mailed Apr. 30, 2015.
[cited by applicant]
Extended European Search Report mailed Nov. 21, 2019 for Application No. EP 19187758.8.
[cited by applicant]
International Preliminary Report on Patentability (Chapter I) for PCT/US2012/060646 mailed Apr. 22, 2014.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2012/060646 mailed Feb. 25, 2013.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2016/050287 mailed Jan. 3, 2017.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2017/030933 mailed Jul. 21, 2017.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2017/030932 mailed Sep. 19, 2017.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2016/050288 mailed Jan. 12, 2016.
[cited by applicant]
[No Author Listed], SQZ Biotech and AskBio Announce Research Collaboration to Create Immune Tolerization Products for AAV Gene Therapies. AskBio. Press Release. Nov. 7, 2019. 3 pages.
[cited by applicant]
[No Author Listed], SQZ Biotech Announces Pricing of Initial Public Offering. SQZ Biotech. Press Release. Oct. 29, 2020. 2 pages.
[cited by applicant]
[No Author Listed], SQZ Biotech Closes $65 Million Series D Financing. SQZ Biotech. Press Release. May 18, 2020. 2 pages.
[cited by applicant]
[No Author Listed], SQZ Biotechnologies Presents Preclinical Data for their SQZ Tolerizing Antigen Carrier Platform in Antigen-Specific Immune Tolerance (ASIT) Digital Summit Invited Talk. SQZ Biotech. Press Release. Ja…
[cited by applicant]
Adamo, Andrea et al., “Microfluidics-Based Assessment of Cell Deformability,” Analytical Chemistry (Aug. 7, 2012), vol. 84, No. 15, pp. 6438-6443.
[cited by applicant]
Alberts et al., Chapter 11: Ion Channels and the Electrical Properties of Membranes. Molecular Biology of the Cell, 4
[cited by applicant]
ATCC Thawing, Propagating, and Cryopreserving Protocol, NCI-PBCF-HTB81 (DU 145), Prostate Carcinoma (ATCC.RTM. htb-81), Version 1.6, 2012, 23 pages.
[cited by applicant]
Augustsson et al. “Microfluidic, Label-Free Enrichment of Prostate Cancer Cells in Blood Based on Acoustophoresis,” Analytical Chemistry, Aug. 28, 2012 (Aug. 28, 2012), vol. 84, No. 18, pp. 7954-7962.
[cited by applicant]
Azarikia et al., Stabilization of biopolymer microgels formed by electrostatic complexation: Influence of enzyme (laccase) cross-linking on pH, thermal, and mechanical stability. Food Res Int. Dec. 2015;78:18-26. doi: 1…
[cited by applicant]
Banz, A. et al., “Tumor Growth Control Using Red Blood Cells as the Antigen Delivery System and Poly(I:C),” J Immunother 2012, 35(5), pp. 409-417.
[cited by applicant]
Baumann et al., Hemolysis of human erythrocytes with saponin affects the membrane structure. Acta Histochem. Feb. 2000;102(1):21-35. doi: 10.1078/0065-1281-00534.
[cited by applicant]
BD Bioscience FITC-labeled anti-CD45 antibody, 2 pages.
[cited by applicant]
BD Bioscience PE-labeled anti-EpCAM antibody, 2 pages.
[cited by applicant]
Berrington et al., Lymphocyte subsets in term and significantly preterm UK infants in the first year of life analysed by single platform flow cytometry. Clin Exp Immunol. May 2005;140(2):289-92. doi: 10.1111/j.1365-2249…
[cited by applicant]
Blagovic et al., 165 Activating antigen carriers generated with microfluidics cell squeezing drive effective anti-tumor responses. JITC. Dec. 2020;8:A98-9. doi: 10.1136/jitc-2020-SITC2020.0165.
[cited by applicant]
Boohaker et al. The Use of Therapeutic Peptides to Target and to Kill Cancer Cells. Curr Med Chem. (2012); 19(22), 26 page reprint.
[cited by applicant]
Bosilkovski, This MIT PhD Just Raised $65 Million for His Clinical Stage Cell Therapy Company. Forbes. May 21, 2020. https://www.forbes.com/sites/igorbosilkovski/2020/05/21/meet-the-mit-phd-who-just-raised-65-million-fo…
[cited by applicant]
Cancer Facts & Figures 2012. Published by the American Cancer Society in Atlanta, 68 pages.
[cited by applicant]
Carlson et al., Self-Sorting of White Blood Cells in a Lattice. PRL. Sep. 15, 1997;79(11):2149-52.
[cited by applicant]
Chaw et al. Multi-step microfluidic device for studying cancer metastasis. Lab on a Chip (2007), v7, p. 1041-1047.
[cited by applicant]
Chen et al., Patch clamping on plane glass-fabrication of hourglass aperture and high-yield ion channel recording. Lab Chip. Aug. 21, 2009;9(16):2370-80. Epub May 14, 2009. https://doi.org/10.1039/b901025d.
[cited by applicant]
Cremel, L. et al., “Innovative approach in Pompe disease therapy: Induction of immune tolerance by antigen-encapsulated red blood cells,” Int J Pharm. Aug. 1, 2015;491(1-2), pp. 69-77.
[cited by applicant]
Cremel, L. et al., “Red blood cells as innovative antigen carrier to induce specific immune tolerance,” Int J Pharm. Feb. 25, 2013;443(1-2), pp. 39-49.
[cited by applicant]
Cross et al., “Nanomechanical analysis of cells from cancer patients,” Nature Nanotechnology (Dec. 2007), vol. 2, pp. 780-783.
[cited by applicant]
De Clercq et al., Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev Med Virol. Nov.-Dec. 2001;11(6):381-95. doi: 10.1002/rmv.336.
[cited by applicant]
De Clercq, Antiviral drugs in current clinical use. J Clin Virol. Jun. 2004;30(2):115-33. doi: 10.1016/j.jcv.2004.02.009.
[cited by applicant]
Ding et al., High-throughput Nuclear Delivery and Rapid Expression of DNA via Mechanical and Electrical Cell-Membrane Disruption. Nat Biomed Eng. 2017;1:0039. doi: 10.1038/s41551-017-0039. Epub Mar. 9, 2017.
[cited by applicant]
Ditommaso et al., Cell engineering with microfluidic squeezing preserves functionality of primary immune cells in vivo. PNAS. Oct. 2018;115(46):E10907-14.
[cited by applicant]
Downs, C. A. et al. (May 14, 2011). “Cell Culture Models Using Rat Primary Alveolar type 1 Cells”, Pulmonary Pharm. & Therapeutics 24(5)577-586.
[cited by applicant]
Eixarch, H. et al. “Tolerance induction in experimental autoimmune encephalomyelitis using non-myeloablative hematopoietic gene therapy with autoantigen.” Molecular Therapy 17.5 (2009): 897-905.
[cited by applicant]
Escoffre et al., What is (still not) known of the mechanism by which electroporation mediates gene transfer and expression in cells and tissues. Mol Biotechnol. Mar. 2009;41(3):286-95. doi: 10.1007/s12033-008-9121-0. Ep…
[cited by applicant]
Esposito et al., “Intraerythrocytic administration of a synthetic Plasmodium antigen elicits antibody response in mice, without carrier molecules or adjuvants,” International Journal of Parasitology, vol. 20, No. 8, pp.…
[cited by applicant]
Fagerlund et al., The Cpf1 CRISPR-Cas protein expands genome-editing tools. Genome Biol. Nov. 17, 2015;16:251. doi: 10.1186/s13059-015-0824-9.
[cited by applicant]
Favretto, M. E. et al., “Human erythrocytes as drug carriers: Loading efficiency and side effects of hypotonic dialysis, chlorpromazine treatment and fusion with liposomes,” Journal of Controlled Release 2013; 170: 343-…
[cited by applicant]
Gasteiger et al. The Proteomics Handbook (2005), Chapter 52, pp. 571-607.
[cited by applicant]
Getasew et al., Advanced malaria treatment in pregnant women. Eur J Clin Pharm. Sep.-Oct. 2017;19(5):325-34.
[cited by applicant]
Gilbert, T-cell-inducing vaccines—what's the future. Immunology. Jan. 2012;135(1):19-26. doi: 10.1111/j.1365-2567.2011.03517.x.
[cited by applicant]
Golzio et al., Direct visualization at the single-cell level of electrically mediated gene delivery. Proc Natl Acad Sci U S A. Feb. 5, 2002;99(3):1292-7. doi: 10.1073/pnas.022646499. Epub Jan. 29, 2002.
[cited by applicant]
Gossett et al., Hydrodynamic stretching of single cells for large population mechanical phenotyping. PNAS. May 2012;109(20):7630-5.
[cited by applicant]
Griesbeck et al., “Sex Differences in Plasmacytoid Dendritic Cell Levels of IRF5 Drive higher IFN-alpha production in Women,” The Journal of Immunology (Dec. 2015), vol. 195(11):5327-5336.
[cited by applicant]
Grimm, A. J. et al., “Memory of tolerance and induction of regulatory T cells by erythrocyte-targeted antigens,” Sci Rep. Oct. 29, 2015;5:15907, 11 pages.
[cited by applicant]
Hallow et al., “Shear-Induced Intracellular Loading of Cells With Molecules by Controlled Microfluidics,” Biotechnology and Bioengineering (2008), vol. 99(4):846-854.
[cited by applicant]
Han, X. et al., “CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation,” Sci. Adv., Aug. 14, 2015, e1500454, 8 pp.
[cited by applicant]
Hillerdal et al., “Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice,” BMC Cancer (Jan. 18, 2014), vol. 14, No. 30, pp. 1-9.
[cited by applicant]
Hoeppener A.E.L.M., Swennenhuis J.F., Terstappen L.W.M.M. (2012) Immunomagnetic Separation Technologies. In: Ignatiadis M., Sotiriou C., Pantel K. (eds) Minimal Residual Disease and Circulating Tumor Cells in Breast Can…
[cited by applicant]
Hoffman, On Red Blood Cells, Hemolysis and Resealed Ghosts. In: The Use of Resealed Erythrocytes as Carriers and Bioreactors. 1992. Magnani et al.,. Eds. Chapter 1:1-15.
[cited by applicant]
Hoskin et al. Studies on anticancer activities of antimicrobial peptides. Biochimica et Biophyscia Acta (2008), v1778, p. 357-375.
[cited by applicant]
Hosokawa et al. Size-Selective Microcavity Array for Rapid and Efficient Detection of Circulating Tumor Cells. Anal. Chem. (2010), v82, p. 6629-6635.
[cited by applicant]
Howarth, M. et al. (May 2008). “Monovalent, Reduced-Size Quantum Dots for Imaging Receptors on Living Cells,” Nature Methods 5(5):397-399.
[cited by applicant]
Janeway Jr et al. Immunobiology: The Immune System in Health and Disease. 5th edition (2001), Chapter “The structure of a typical antibody molecule”, NCBI Bookshelf NBK27144, 5 page reprint.
[cited by applicant]
Jiang, The immunopotentiators and delivery systems for use in vaccines. Prog Microbiol Immunol. Dec. 31, 2012;(3):1-8.
[cited by applicant]
Johnson et al., Loss of resealing ability in erythrocyte membranes. Effect of divalent cations and spectrin release. Biochim Biophys Acta. May 4, 1978;509(1):58-66. doi: 10.1016/0005-2736(78)90007-x. Abstract only.
[cited by applicant]
Kiani et al., Cas9 gRNA engineering for genome editing, activation and repression. Nature Methods. 2015;12:1051-4.
[cited by applicant]
Kim, D., et al., “Microengineered Platforms for Cell Mechanobiology,” Annual Review of Biomedical Engineering, 2009, vol. 11, pp. 203-233.
[cited by applicant]
Kinosita Jr et al., Survival of sucrose-loaded erythrocytes in the circulation. Nature. Mar. 1, 19786;272(5650):258-60. doi: 10.1038/272258a0.
[cited by applicant]
Lee et al., “Nonendocytic delivery of functional engineered nanoparticles into the cytoplasm of live cells using a novel, high-throughput microfluidic device,” Nano Letters (2012), vol. 12, pp. 6322-6327.
[cited by applicant]
Lee et al., Kinetic studies of human erythrocyte membrane resealing. Biochim Biophys Acta. Apr. 2, 19856;815(1):128-34. doi: 10.1016/0005-2736(85)90482-1. Abstract only.
[cited by applicant]
Li, J et al., “Microfluidic-Enabled Intracellular Delivery of Membrane Impermeable Inhibitors to Study Target Engagement in Human Primary Cells,” ACS Chemical Biology 2017, vol. 12, No. 12, pp. 2970-2974.
[cited by applicant]
Lin et al., “Highly selective biomechanical separation of cancer cells from leukocytes using microfluidic and hydrodynamic concentrator,” Biomicrofluidics (Jun. 26, 2013), vol. 7, No. 3, p. 34114-1-11.
[cited by applicant]
Liu et al., “Molecular imaging in tracking tumor-specific cytotoxic T lymphocytes (CTLs),” Theranostics (Jul. 28, 2014), vol. 4, No. 10, pp. 990-1001.
[cited by applicant]
Liu et al., “Spatially selective reagent delivery into cancer cells using a two-layer microfluidic culture system,” Analytica Chimica Acta (Sep. 1, 2012), vol. 743, pp. 125-130.
[cited by applicant]
Liu, W et al. (Jan. 20, 2010). “Compact Biocompatible Quantum Dots Via RAFT-Mediated Synthesis of Imidazole-Based Random Copolymer Ligand,” JACS 132(2):472-483.
[cited by applicant]
Lizano et al., Mouse erythrocytes as carriers for coencapsulated alcohol and aldehyde dehydrogenase obtained by electroporation in vivo survival rate in circulation, organ distribution and ethanol degradation. Life Sci.…
[cited by applicant]
Lorentz, K. M et al., “Engineered binding to erythrocytes induces immunological tolerance to E. coli asparaginase,” Sci Adv. Jul. 17, 2015;1(6):e1500112, 11 pages.
[cited by applicant]
Magnani et al., Erythrocyte engineering for drug delivery and targeting. Biotechnol Appl Biochem. Aug. 1998;28(1):1-6.
[cited by applicant]
Mali, p et al., “RNA-guided human Genome Engineering via Cas9,” Science (2013), vol. 339, No. 6121, pp. 823-826.
[cited by applicant]
Maratou et al., Glucose transporter expression on the plasma membrane of resting and activated while blood cells. European Journal of Clinical Investigation. 2007;37:282-90.
[cited by applicant]
Matthews, B.D., et al., “Cellular adaptation to mechanical stress: role of integrins, Rho, cytoskeletal tension and mechanosensitive ion channels,” Journal of Cell Science, vol. 119, pp. 508-518, 2006.
[cited by applicant]
McNeil et al., Coping with the inevitable: how cells repair a torn surface membrane. Nat Cell Biol. May 2001;3(5):E124-9. doi: 10.1038/35074652. Abstract only.
[cited by applicant]
McNeil et al., Plasma membrane disruption: repair, prevention, adaptation. Annu Rev Cell Dev Biol. 2003;19:697-731. doi: 10.1146/annurev.cellbio.19.111301.140101.
[cited by applicant]
McNeil et al., The endomembrane requirement for cell surface repair. Proc Natl Acad Sci U S A. Apr. 15, 2003;100(8):4592-7. doi: 10.1073/pnas.0736739100. Epub Apr. 2, 2003.
[cited by applicant]
McNeil, Repairing a torn cell surface: make way, lysosomes to the rescue. J Cell Sci. Mar. 1, 2002;115(Pt 5):873-9.
[cited by applicant]
Milo, R. “What is the total number of protein molecules per cell volume? A call to rethink some published values.” Bioessays 35.12 (2013): 1050-1055.
[cited by applicant]
Murphy, J. S. et al. (Sep. 1, 1956, e-pub May 2004). “Measurement of Wall Shearing Stress in the Boundary Layer by Means of an Evaporating Liquid Film,” Journal of Applied Physics 27(9):1097-1103.
[cited by applicant]
Nagel et al., HbS-oman heterozygote: a new dominant sickle syndrome. Blood. Dec. 1, 1998;92(11):4375-82.
[cited by applicant]
Nic An Tsaoir et al., Scalable Antibody Production from CHO Cell Line of Choice Using Flow Electroporation. MaxCyte. Jun. 2016. 1 page.
[cited by applicant]
Novokhatskiy et al., Problema kontaminatsii kletkami I novyie podkhody k kontroliu perevivaiemykh liniy. Voprosy virusologii. 1977;4:396-408.
[cited by applicant]
Ogurtsov et al., Biotechnology. Principles and Application Training Manual. Ministry of Education and Science. 2012. 344 pages.
[cited by applicant]
Paganin-Gioanni et al., Direct visualization at the single-cell level of siRNA electrotransfer into cancer cells. Proc Natl Acad Sci U S A. Jun. 28, 2011;108(26):10443-7. doi: 10.1073/pnas.1103519108. Epub Jun. 13, 2011.
[cited by applicant]
Patel et al., Drug loaded erythrocytes: as novel drug delivery system. Curr Pharm Des. 2008;14(1):63-70. doi: 10.2174/138161208783330772.
[cited by applicant]
Polvani et al., “Murine Red Blood Cells as Efficient Carriers of Three Bacterial Antigens for the Production of Specific and Neutralizing Antibodies,” Biotechnology and Applied Biochemistry, vol. 14, pp. 347-356 (1991).
[cited by applicant]
Ramakrishnan et al., 1743-P: Engineering Erythrocytes with the SQZ Cell Therapy Platform to Enhance Immunotolerance. Diabetes. Jun. 2019;68(Supplement 1). https://doi.org/10.2337/db19-1743-P. Abstract.
[cited by applicant]
Ravilla et al., “Erythrocytes as Carrier for Drugs, Enzymes and Peptides,” Journal of Applied Pharmaceutical Science, vol. 2, No. 2, pp. 166-176 (2012).
[cited by applicant]
Razizadeh et al., Coarse-Grained Modeling of Pore Dynamics on the Red Blood Cell Membrane under Large Deformations. Biophys J. Aug. 4, 2020;119(3):471-482. doi: 10.1016/j.bpj.2020.06.016. Epub Jun. 24, 2020.
[cited by applicant]
Reddy et al., Plasma membrane repair is mediated by Ca(2+)-regulated exocytosis of lysosomes. Cell. Jul. 27, 2001;106(2):157-69. doi: 10.1016/s0092-8674(01)00421-4.
[cited by applicant]
Redman, Phospholipid metabolism in intact and modified erythrocyte membranes. J Cell Biol. Apr. 1971;49(1):35-49. doi: 10.1083/jcb.49.1.35.
[cited by applicant]
Rossi, L. et al., “Erythrocyte-mediated delivery of phenylalanine ammonia lyase for the treatment of phenylketonuria in BTBR-Pah.sup.enu2 mice,” Journal of Controlled Release 194; 37-44 (2014).
[cited by applicant]
Rughetti, A. et al., “Transfected human dendritic cells to induce antitumor immunity,” Gene Therapy, vol. 7, pp. 1458-1466 (2000).
[cited by applicant]
Rutella et al., “Tolerogenic dendritic cells: cytokine modulation comes of age,” Blood, vol. 108, No. 5, pp. 1435-1440 (2006).
[cited by applicant]
Sachs, Potassium-potassium exchange as part of the over-all reaction mechanism of the sodium pump of the human red blood cell. J Physiol. May 1986;374:221-44. doi: 10.1113/jphysiol.1986.sp016076.
[cited by applicant]
Salgado et al., Red blood cell membrane-facilitated release of nitrite-derived nitric oxide bioactivity. Biochemistry. Nov. 10, 2015;54(44):6712-23. doi: 10.1021/acs.biochem.5b00643. Epub Oct. 28, 2015. Abstract only.
[cited by applicant]
Saulis, The loading of human erythrocytes with small molecules by electroporation. Cell Mol Biol Lett. 2005;10(1):23-35.
[cited by applicant]
Schatzmann et al., Calcium movements across the membrane of human red cells. J Physiol. Apr. 1969;201(2):369-95. doi: 10.1113/jphysiol.1969.sp008761.
[cited by applicant]
Sharei et al, “Ex vivo Cytosolic Delivery of Functional Macromolecules to Immune Cells,” (Apr. 13, 2015), PLoS One, vol. 10, No. 4, 12 pp. e0118803.
[cited by applicant]
Sharei et al., “A vector-free microfluidic platform for intracellular delivery,” Proc. Natl. Acad. Sci. USA (Feb. 5, 2013), vol. 110, No. 6, pp. 2082-2087.
[cited by applicant]
Sharei et al., “A vector-free microfluidic platform for intracellular delivery,” Proc. Natl. Acad. Sci. USA (Feb. 5, 2013), vol. 110, No. 6, Supporting Information. 10 pages.
[cited by applicant]
Sharei et al., “Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform,” Journal of Visualized Experiments (Nov. 7, 2013), No. 81, 9 pp.
[cited by applicant]
Sharei et al., “Plasma membrane recovery kinetics of a microfluidic intracellular delivery platform,” Integrative Biology (2014), vol. 6, pp. 470-475.
[cited by applicant]
Shelby et al., “A microfluidic model for single-cell capillary obstruction by Plasmodium falciparum infected erythrocytes,” (Dec. 9, 2003), Proc. Nat. Acad. Sci., vol. 100, No. 25, pp. 14618-14622.
[cited by applicant]
Song et al., Scientific basis for the use of hypotonic solutions with ultrasonic liposuction. Aesthetic Plast Surg. Mar.-Apr. 2006;30(2):233-8. doi: 10.1007/s00266-005-0087-z.
[cited by applicant]
Steinman et al., “Tolerogenic dendritic cells,” Annual Review of Immunology, vol. 21, pp. 685-711 (2003).
[cited by applicant]
Stevenson et al., Single cell optical transfection. J R Soc Interface. Jun. 6, 2010;7(47):863-71. doi: 10.1098/rsif.2009.0463. Epub Jan. 11, 2010.
[cited by applicant]
Stevenson, D. J. et al., “Single cell optical transfection,” IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control, vol. 53, No. 1, 863-871 (2010).
[cited by applicant]
Stewart et al., “In vitro and ex vivo strategies for intracellular delivery,” Nature, vol. 538, No. 7624, pp. 183-192 (2016).
[cited by applicant]
Swaminathan et al. Mechanical Stiffness Grades Metastatic Potential in Patient Tumor Cells and in Cancer Cell Lines. Cancer Research (2011) , v71(15), p. 5075-5080.
[cited by applicant]
Szeto et al., “Microfluidic squeezing for intracellular antigen loading in polyclonal B-cells as cellular vaccines,” Scientific Reports, vol. 5, 10276 (May 2015), 13 pages.
[cited by applicant]
Tlaxca et al., Analysis of in vitro transfection by sonoporation using cationic and neutral microbubbles. Ultrasound Med Biol. Nov. 2010;36(11):1907-18. doi: 10.1016/j.ultrasmedbio.2010.05.014.
[cited by applicant]
Tran et al., Expansion of immature, nucleated red blood cells by transient low-dose methotrexate immune tolerance induction in mice. Clin Exp Immunol. Nov. 18, 2020;0:1-15. doi: 10.1111/cei.13552.
[cited by applicant]
Vechkanov et al., Osnovy kletochnoy inzhenerii: Study guide. Rostov-on-Don. 2012; 133 pages. Relevant pp. 15-16.
[cited by applicant]
Vinulan, SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D. Xconomy. Oct. 12, 2020. https://xconomy.com/boston/2020/10/12/sqz-biotech-lines-up-an-ipo-on-the-nyse-to-fund-cell-therapy-rd/ [last accessed Ja…
[cited by applicant]
Weaver et al., A brief overview of electroporation pulse strength-duration space: A region where additional intracellular effects are expected. Bioelectrochemistry. Oct. 2012;87:236-43.
[cited by applicant]
Wen et al., Shear Effects on Stability of DNA Complexes in the Presence of Serum. Biomacromolecules. Oct. 9, 2017;18(10):3252-3259. doi: 10.1021/acs.biomac.7b00900. Epub Sep. 1, 2017.
[cited by applicant]
Williams, A.R. et al. (Nov. 5, 1999). “Filtroporation: A Simple, Reliable Technique for Transfection and Macromolecular Loading of Cells”, Biotechnology and Bioengineering 65(3)341-346.
[cited by applicant]
Wright et al., Rational design of a split-Cas9 enzyme complex. PNAS. Mar. 2015;112(10):2984-9.
[cited by applicant]
Yangulov et al., Vliyaniye razlichnykh kriozashchitnykh sred na zhiznesposobnost kriokonservirovannykh limfoblastnykh kletochnyk liniy H-9 I U-937. Problemy kriobiologii. 1991;3:46-9.
[cited by applicant]
Ye, Complexation between milk proteins and polysaccharides via electrostatic interaction: principles and applications—a review. Int J Food Sci Technol. Jan. 31, 2008;43(3):406-15.
[cited by applicant]
Yin et al., “Delivery technologies for genome editing,” Nature Reviews (2017), vol. 16, No. 6, pp. 387-399.
[cited by applicant]
Zarnitsyn et al., “Electrosonic ejector microarray for drug and gene delivery,” Biomed Microdevices (2008) 10:299-308.
[cited by applicant]
Zdobnova et al., Self-Assembling Complexes of Quantum Dots and scFv Antibodies for Cancer Cell Targeting and Imaging. PLoS One. 2012;7(10):e48248. 8 pages.
[cited by applicant]
Zhdanov et al., Tayna tretiego tsarstva. Znaniye. 1975; 176 p. Relevant pp. 124-125.
[cited by applicant]
U.S. Appl. No. 17/404,286, filed Aug. 17, 2021, Sharei et al.
[cited by applicant]
U.S. Appl. No. 17/394,125, filed Aug. 4, 2021, Sharei et al.
[cited by applicant]
U.S. Appl. No. 17/075,116, filed Oct. 20, 2020, Sharei et al.
[cited by applicant]
U.S. Appl. No. 17/509,229, filed Oct. 25, 2021, Sharei et al.
[cited by applicant]
PCT/US2016/041653, Jan. 18, 2018, International Preliminary Report on Patentability (Chapter I).
[cited by applicant]
PCT/US2016/041653, Oct. 4, 2016, International Search Report and Written Opinion.
[cited by applicant]
EP 16737769.6, May 3, 2018, Extended European Search Report.
[cited by applicant]
PCT/US2016/013113, Mar. 21, 2016, International Search Report and Written Opinion.
[cited by applicant]
PCT/US2016/013113, Jul. 27, 2017, International Preliminary Report on Patentability (Chapter I).
[cited by applicant]
EP 15859824.3, Jun. 11, 2018, Partial Supplementary European Search Report.
[cited by applicant]
EP 15859824.3, Sep. 11, 2018, Extended European Search Report.
[cited by applicant]
PCT/US2015/060689, May 16, 2017, International Preliminary Report on Patentability (Chapter I).
[cited by applicant]
PCT/US2015/060689, Feb. 1, 2016, International Search Report and Written Opinion.
[cited by applicant]
EP 15855640.7, May 30, 2018, Partial Supplementary European Search Report.
[cited by applicant]
EP 15855640.7, Sep. 5, 2018, Extended European Search Report.
[cited by applicant]
PCT/US2015/058489, May 2, 2017, International Preliminary Report on Patentability (Chapter I).
[cited by applicant]
PCT/US2015/058489, Mar. 11, 2016, International Search Report and Written Opinion.
[cited by applicant]
EP 14836593.5, Feb. 23, 2017, European Search Report.
[cited by applicant]
EP 21158382.8, Jun. 11, 2021, Extended European Search Report.
[cited by applicant]
PCT/US2014/051343, Feb. 16, 2016, International Preliminary Report on Patentability (Chapter I).
[cited by applicant]
PCT/US2014/051343, Dec. 18, 2014, International Search Report and Written Opinion.
[cited by applicant]
EP 12841329.1, Apr. 30, 2015, European Search Report.
[cited by applicant]
EP 19187758.8, Nov. 21, 2019, Extended European Search Report.
[cited by applicant]
PCT/US2012/060646, Apr. 22, 2014, International Preliminary Report on Patentability (Chapter I).
[cited by applicant]
PCT/US2012/060646, Feb. 25, 2013, International Search Report and Written Opinion.
[cited by applicant]
PCT/US2016/050287, Jan. 3, 2017, International Search Report and Written Opinion.
[cited by applicant]
PCT/US2017/030933, Jul. 21, 2017, International Search Report and Written Opinion.
[cited by applicant]
PCT/US2017/030932, Sep. 19, 2017, International Search Report and Written Opinion.
[cited by applicant]
PCT/US2016/050288, Jan. 12, 2016, International Search Report and Written Opinion.
[cited by applicant]
Extended European Search Report for EP Application No. 23174770.0 dated Dec. 4, 2023.
[cited by applicant]
Adamo et al., Microfluidic Cell Deformation as a Robust, Vector-Free Method for Cystosolic Delivery of Macromolecules. 2012 AlChE Annual Meeting. Oct. 2012;8 pages.
[cited by applicant]
Brahmer et al., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. Jun. 28, 2012;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub Jun. 2, 2012.
[cited by applicant]
Cobb et al., Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine. J Immunol Methods. Feb. 28, 2011;365(1-2):27-37. doi: 10.1016/j.jim.2010.11.002. Epub Nov. 18, 2010.
[cited by applicant]
Hombach et al., Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined…
[cited by applicant]
Kim et al., Blocking the immunosuppressive axis with small interfering RNA targeting interleukin (IL)-10 receptor enhances dendritic cell-based vaccine potency. Clin Exp Immunol. Aug. 2011;165(2):180-9. doi: 10.1111/j.1…
[cited by applicant]
Lin et al., Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. Elife. Dec. 15, 2014;3:e04766. doi: 10.7554/eLife.04766.
[cited by applicant]
Liu et al., Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood. Jul. 1, 20…
[cited by applicant]
Madan et al., Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. May 2012;13(5):501-8. doi: 10.1016/S…
[cited by applicant]
Nemudryi et al., TALEN and CRISPR/Cas Genome Editing Systems: Tools of Discovery. Acta Naturae. Jul. 2014;6(3):19-40.
[cited by applicant]
Rivera-Torres et al., The position of DNA cleavage by TALENs and cell synchronization influences the frequency of gene editing directed by single-stranded oligonucleotides. PLoS One. May 1, 2014;9(5):e96483. doi: 10.137…
[cited by applicant]
Stronen et al., Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells. Scand J Immunol. Apr. 2009;69(4):319-28. doi: 10.1111/…
[cited by applicant]
Wang et al., Delivery of siRNA therapeutics: barriers and carriers. AAPS J. Dec. 2010;12(4):492-503. doi: 10.1208/s12248-010-9210-4. Epub Jun. 11, 2010.
[cited by applicant]
Kalos et al., T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. Aug. 10, 2011;3(95):95ra73. doi: 10.1126/scitranslmed.3002…
[cited by applicant]
Molday et al., X-linked juvenile retinoschisis: clinical diagnosis, genetic analysis, and molecular mechanisms. Prog Retin Eye Res. May 2012;31(3):195-212. doi: 10.1016/j.preteyeres.2011.12.002. Epub Jan. 3, 2012.
[cited by applicant]
Chen et al., Cationic nanoparticles induce nanoscale disruption in living cell plasma membranes. J Phys Chem B. Aug. 13, 2009;113(32):11179-85. doi: 10.1021/jp9033936.
[cited by applicant]
Diez-Silva et al., Shape and Biomechanical Characteristics of Human Red Blood Cells in Health and Disease. MRS Bull. May 2010;35(5):382-388. doi: 10.1557/mrs2010.571.
[cited by applicant]
Grover et al., Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin Cancer Res. Oct. 1, 2006;12(19):5801-8. doi: 10.1158/1078-0432.CCR-05-2421.
[cited by applicant]